Subscribe To
Ultragenyx (rare) doses first patients in bone disease studies
Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients wit...
July 7, 2023, 9:23 am
Ultragenyx (rare) posts data from osteogenesis imperfecta study
Ultragenyx (RARE), along with partner Mereo BioPharma, announces encouraging data on mid-stage study evaluating setrusumab for patients with ...
June 6, 2023, 12:14 pm
Ultragenyx and mereo biopharma to present setrusumab data update at asbmr
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx�...
September 9, 2022, 8:22 pm